Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4856659
Max Phase: Preclinical
Molecular Formula: C54H72F15N13O16
Molecular Weight: 874.11
Molecule Type: Unknown
Associated Items:
ID: ALA4856659
Max Phase: Preclinical
Molecular Formula: C54H72F15N13O16
Molecular Weight: 874.11
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(=O)N[C@H](CCCN)C(=O)NC(=O)[C@H](C)NC(=O)[C@H](CCNC(=N)N)NCCN1CCN(CCCC2CCN(CC(=O)N3c4ccccc4NC(=O)c4ccccc43)CC2)CC1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
Standard InChI: InChI=1S/C44H67N13O6.5C2HF3O2/c1-30(40(60)53-43(63)36(12-7-18-45)51-31(2)58)50-42(62)35(15-19-49-44(46)47)48-20-24-55-27-25-54(26-28-55)21-8-9-32-16-22-56(23-17-32)29-39(59)57-37-13-5-3-10-33(37)41(61)52-34-11-4-6-14-38(34)57;5*3-2(4,5)1(6)7/h3-6,10-11,13-14,30,32,35-36,48H,7-9,12,15-29,45H2,1-2H3,(H,50,62)(H,51,58)(H,52,61)(H4,46,47,49)(H,53,60,63);5*(H,6,7)/t30-,35-,36+;;;;;/m0...../s1
Standard InChI Key: PRPSLWLCCSUXRU-PFJBEOSVSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 874.11 | Molecular Weight (Monoisotopic): 873.5337 | AlogP: 0.25 | #Rotatable Bonds: 21 |
Polar Surface Area: 263.45 | Molecular Species: BASE | HBA: 12 | HBD: 9 |
#RO5 Violations: 3 | HBA (Lipinski): 19 | HBD (Lipinski): 11 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.38 | CX Basic pKa: 12.00 | CX LogP: -2.20 | CX LogD: -7.12 |
Aromatic Rings: 2 | Heavy Atoms: 63 | QED Weighted: 0.06 | Np Likeness Score: -0.31 |
1. Weinhart CG, Wifling D, Schmidt MF, Neu E, Höring C, Clark T, Gmeiner P, Keller M.. (2021) Dibenzodiazepinone-type muscarinic receptor antagonists conjugated to basic peptides: Impact of the linker moiety and unnatural amino acids on M2R selectivity., 213 [PMID:33571911] [10.1016/j.ejmech.2021.113159] |
Source(1):